GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Telo Genomics Corp (OTCPK:TDSGF) » Definitions » Capital Expenditure
中文

Telo Genomics (Telo Genomics) Capital Expenditure : $-0.02 Mil (TTM As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Telo Genomics Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Telo Genomics's cash flow for capital expenditures for the three months ended in Dec. 2023 was $0.00 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.02 Mil.


Telo Genomics Capital Expenditure Historical Data

The historical data trend for Telo Genomics's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telo Genomics Capital Expenditure Chart

Telo Genomics Annual Data
Trend Dec13 Dec14 Dec15 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Capital Expenditure
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -0.01 -0.01 -0.02 -0.05

Telo Genomics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.02 - - -

Telo Genomics Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Telo Genomics (Telo Genomics) Business Description

Traded in Other Exchanges
Address
101 College Street, Suite 200, MaRS Centre, South Tower, Toronto, ON, CAN, M5G 1L7
Telo Genomics Corp is a personalized medicine company. The company through its wholly-owned subsidiary is engaged in the development and commercialization of diagnostic and prognostic products. The company is developing diagnostic and prognostic products for cancer and neurological disorders.